These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26424330)

  • 1. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
    Gautier JF; Martinez L; Penfornis A; Eschwège E; Charpentier G; Huret B; Madani S; Gourdy P
    Adv Ther; 2015 Sep; 32(9):838-53. PubMed ID: 26424330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
    Martinez L; Penfornis A; Gautier JF; Eschwège E; Charpentier G; Bouzidi A; Gourdy P
    Adv Ther; 2017 Mar; 34(3):674-685. PubMed ID: 28138803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
    Bode BW; Brett J; Falahati A; Pratley RE
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
    Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A;
    Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
    Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
    Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.
    Abusnana S; Al Awadi F; Aly H; Bashier A; Kumar Dhanwal D; Halasa T; Jallo M; Medina J; Singhal S
    Diabetes Res Clin Pract; 2023 Feb; 196():110183. PubMed ID: 36436550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Zdravkovic M; Kaku K
    Diabetes Res Clin Pract; 2008 Aug; 81(2):161-8. PubMed ID: 18495285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.
    Fujishima Y; Maeda N; Inoue K; Kashine S; Nishizawa H; Hirata A; Kozawa J; Yasuda T; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2012 Sep; 11():107. PubMed ID: 22973968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.
    Buysman EK; Sikirica MV; Thayer SW; Bogart M; DuCharme MC; Joshi AV
    J Comp Eff Res; 2018 Feb; 7(2):89-100. PubMed ID: 28814107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
    D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
    Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.